Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from . a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.
/PRNewswire/ ImmuneID - a biopharmaceutical company that uses existing antibody responses to rapidly unveil the complexities of the immune system, thereby.
Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics
- Funds to Support Expansion of CIVO® Technology Platform
- New Collaborations to Utilize CIVO for Phase 0 Studies
News provided by
Share this article
Share this article
SEATTLE, March 2, 2021 /PRNewswire/ Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative
In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.